Emergence of coagulase-negative staphylococci
K Becker, A Both, S Weißelberg… - Expert review of anti …, 2020 - Taylor & Francis
ABSTRACT Introduction: Compared to Staphylococcus aureus, coagulase-negative
staphylococci (CoNS) are characterized by a lower capacity to cause acute, live-threatened …
staphylococci (CoNS) are characterized by a lower capacity to cause acute, live-threatened …
[HTML][HTML] Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: expert review panel
Background Dalbavancin is a lipoglycopeptide with a long elimination half-life and is
currently licensed for the treatment of acute bacterial skin and skin structure infections in …
currently licensed for the treatment of acute bacterial skin and skin structure infections in …
Antibiotic approvals in the last decade: are we kee** up with resistance?
EB Chahine, JA Dougherty… - Annals of …, 2022 - journals.sagepub.com
Objective: To review the spectrum of activity, efficacy, safety, and role in therapy of all
antibiotics and related biologics approved by the Food and Drug Administration (FDA) in the …
antibiotics and related biologics approved by the Food and Drug Administration (FDA) in the …
Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet …
Dalbavancin is a novel, long-acting lipoglycopeptide characterized by a long elimination half-
life coupled with excellent in vitro activity against multidrug-resistant Gram-positives …
life coupled with excellent in vitro activity against multidrug-resistant Gram-positives …
Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections
JT Bork, EL Heil, S Berry, E Lopes, R Davé… - Infectious Diseases and …, 2019 - Springer
Introduction Dalbavancin is approved for acute bacterial skin and skin structure infections
(ABSSSIs) but offers a potential treatment option for complicated invasive gram-positive …
(ABSSSIs) but offers a potential treatment option for complicated invasive gram-positive …
Dalbavancin in bone and joint infections: a systematic review
S Lovatti, G Tiecco, A Mule, L Rossi, A Sforza, M Salvi… - Pharmaceuticals, 2023 - mdpi.com
Background: Approved for acute bacterial skin and skin structure infections, dalbavancin
(DBV) has gradually acquired over the years a role as an off-label treatment for several …
(DBV) has gradually acquired over the years a role as an off-label treatment for several …
Biofilm-related infections in gram-positive bacteria and the potential role of the long-acting agent dalbavancin
A Oliva, S Stefani, M Venditti… - Frontiers in …, 2021 - frontiersin.org
Infections caused by Gram-positive bacteria are a major public health problem due to their
increasing resistance to antibiotics. Staphylococcus and Enterococcus species' resistance …
increasing resistance to antibiotics. Staphylococcus and Enterococcus species' resistance …
French national cohort of first use of dalbavancin: a high proportion of off-label use
A Dinh, C Duran, P Pavese, L Khatchatourian… - International journal of …, 2019 - Elsevier
Dalbavancin is a glycopeptide antibiotic with a long half-life, recently marketed in Europe for
skin and soft-tissue infections (SSTIs), but its real-life use is not well known. The aim of this …
skin and soft-tissue infections (SSTIs), but its real-life use is not well known. The aim of this …
Population pharmacokinetic and pharmacodynamic analysis of dalbavancin for long-term treatment of subacute and/or chronic infectious diseases: the major role of …
PG Cojutti, S Tedeschi, M Gatti, E Zamparini… - Antibiotics, 2022 - mdpi.com
A population pharmacokinetic analysis of dalbavancin was conducted in patients with
different infection sites. Non-linear mixed effect modeling was used for pharmacokinetic …
different infection sites. Non-linear mixed effect modeling was used for pharmacokinetic …
Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections
Objective: To assess the efficacy and safety of dalbavancin compared to standard-of-care
(SOC) or vancomycin and daptomycin in invasive infections due to suspected or confirmed …
(SOC) or vancomycin and daptomycin in invasive infections due to suspected or confirmed …